Camarillo, California-based Kinamed Incorporated has announced Vineet K. Sarin, Ph.D. has joined the firm and will serve its new president and chief executive officer. Dr. Sarin will replace Clyde Pratt, who was CEO for Kinamed for 29 years. Dr. Sarin has been with Kinamed for over 20 years, serving as president since 2008 and a member of its Board of Directors since 2015.
Kinamed is a leading specialty medical device company, focused on the development and manufacturing of specialty ortho, cardiothoracic, and neurosurgical tools.
The company’s innovative products include the SuperCable Iso Elastic Polymer Cerclage system, the KineMatch Patello-Femoral Replacement, the MD3T™ Multi-Directional Tibial Tubercle Transfer instrumentation, and the CarboJet bone preparation system, all unique innovations in surgical care. Kinamed has, to date, produced and manufactured more than 3 million implants, for use in over 30 countries.
“I am thrilled to appoint Vineet as President and CEO of Kinamed,” stated Pratt, who will continue to serve as chairman of the Board. “This new chapter comes at a time of great promise for our Company. Vineet is exceptionally well-qualified for his new role, and I very much look forward to our next chapter under his leadership. Most recently, as President, Vineet led the development and execution of our strategic plan while successfully navigating a challenging Covid environment. Vineet’s skills and experiences position him as the ideal person to lead Kinamed through our next phase of growth.”
Dr. Sarin studied biomedical engineering at Duke University, went on to earn a master’s degree in biomechanical engineering and a doctorate in mechanical engineering from Stanford University. He has written and contributed over 50 scientific papers and holds more than 20 surgical device patents. Dr. Sarin previously assisted in developing Kinamed’s cutting edge and proprietary orthopedic product portfolio, earning the company a 10% compounded annual growth rate during the years before the pandemic as well as ongoing expansion during the Covid-era.
Dr. Sarin told OTW, “My top near-term objectives are to:
- Establish SuperCable as the cerclage cable system of choice for ASCs [ambulatory surgery centers] and outpatient centers.
- Advance CarboJet XF as the optimal bone preparation and cleaning system for cemented arthroplasty,
- Advance the market adoption of KineMatch as the preferred treatment for patients with isolated, end-stage patello-femoral osteoarthritis, and,
- Introduce MD3T to sports medicine surgeons as the most versatile method for performing transfer of the Tibial Tubercle.”
“I am honored and excited to lead Kinamed during the next chapter of our history,” said Dr. Sarin. “My experiences up to this point have provided deep knowledge of all phases of the medical device lifecycle, from conceptualization and development of a novel idea all the way through post-market clinical validation. All the while, I have learned the importance of strategic vision and operational excellence. Looking ahead, I am especially excited about the impact that our unique, proprietary, highly differentiated, and clinically proven products are having on the outpatient surgery and joint preservation markets. In particular, our flagship product lines, SuperCable and CarboJet, are growing well above market rates while a substantial and growing body of clinical evidence supports the value proposition across all of our core product lines.”
